MYCN and neuroblastoma: Likewise, targeting a non-coding region adjacent to MYCN with Cas9D10A led to the rapid depletion of MYCN-amplified neuroblastoma cell lines (SK-N-BE(2 C), KELLY, NGP, CHP-212, and IMR-32) in a dose-dependent manner (Fig. 2B).